PF-562271 hydrochloride
Based on 30 publication(s) in Google Scholar
PF-562271 (VS-6062) hydrochloride is a potent, ATP-competitive and reversible FAK and Pyk2 kinase inhibitor with IC50s of 1.5 nM and 13 nM, respectively.
For research use only. We do not sell to patients.
- Purity: 98.10%
- CAS No.: 939791-41-0
- Formula: C21H21ClF3N7O3S
- Molecular Weight:543.95
-
Storage:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Multi-Target Compound Library
HY-L176
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Protein Kinase Compound Library
HY-L196
-
High-Throughput Bioactive Compound Library
HY-L205
-
Kinase Inhibitor Library
HY-L009
-
Protein Tyrosine Kinase Compound Library
HY-L016
-
Anti-Cancer Compound Library
HY-L025
-
Cytoskeleton Compound Library
HY-L060
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Anti-Pulmonary Fibrosis Compound Library
HY-L125
-
Heterocyclic Compound Library
HY-L138
Publications Citing Use of MedChemExpress (MCE) PF-562271 hydrochloride
More- Nat Biomed Eng. 2025 Nov 3. [Abstract]
- Cancer Res. 2013 May 1;73(9):2873-83. [Abstract]
- Autophagy. 2026 May 29:1-15. [Abstract]
- Cell Discov. 2022 Sep 6;8(1):84. [Abstract]
- Carbohydr Polym. 2024 Feb 15:326:121637. [Abstract]
- Cell Death Dis. 2023 Feb 24;14(2):157. [Abstract]
- Cell Death Dis. 2022 Sep 10;13(9):783. [Abstract]
- Clin Cancer Res. 2019 Jul 15;25(14):4552-4566. [Abstract]
- Int J Surg. 2025 Sep 17. [Abstract]
- Am J Chin Med. 2025;53(4):1225-1240. [Abstract]
- World J Gastroenterol. 2025 Jul 28;31(28):107361. [Abstract]
- Cell Rep. 2023 Oct 5;42(10):113213. [Abstract]
- Life Sci. 2021 Apr 1:270:119112. [Abstract]
- Breast Cancer Res. 2024 Mar 19;26(1):48. [Abstract]
- Sci Rep. 2018 May 8;8(1):7228. [Abstract]
- Int J Cancer. 2015 Oct 1;137(7):1549-59. [Abstract]
- Cell Signal. 2025 Sep 10:136:112117. [Abstract]
- Environ Toxicol Pharmacol. 2023 Nov:104:104301. [Abstract]
- Eur J Cell Biol. 2024 May 28;103(2):151427. [Abstract]
- Cancer Med. 2025 Sep;14(18):e71227. [Abstract]
- Mol Biol Rep. 2026 May 14;53(1):770. [Abstract]
- Mol Biol Rep. 2025 May 14;52(1):458. [Abstract]
- J Nat Med. 2020 Sep;74(4):732-740. [Abstract]
- Anticancer Drugs. 2024 Jan 1;35(1):46-54. [Abstract]
- Res Sq. 2025 Jul 11.
- bioRxiv. 2025 May 28.
- bioRxiv. 2025 Apr 7:2025.04.01.646098. [Abstract]
- Research Square Preprint. 2023 May 23.
- Research Square Preprint. 2021 Dec.
- Practical Oncology Journal. 2015, 29(5): 444-449.
Customer Validation & Images
-
WB
-
WB
-
WB
-
WB
Biological Activity
IC50: 1.5 nM (FAK), 13 nM (Pyk2), 30 nM (CDK2), 47 nM (CDK3), 58 nM (CDK1), 97 nM (CDK7), 97 nM (Flt3)[1]
PF-562271 (VS-6062) hydrochloride is shown to be a 30- to 120-nM inhibitor of CDK2/E, CDK5/p35, CDK1/B, and CDK3/E in recombinant enzyme assays, in cell-based assays evaluating the role of CDKs, a 48-hour exposure of 3.3 μM PF-562271 is required to alter cell cycle progression. PF-562271 is potent in an inducible cell-based assay measuring phospho-FAK with a IC50 of 5 nM[1].
PF-562271, a selective inhibitor of both FAK and proline-rich tyrosine kinase 2 (PYK2), a FAK-related family member, on cell growth and colony formation in Ewing sarcoma cell lines. Seven cell lines are treated for 5 days with PF-562271 across a range of concentrations using 2-fold serial dilutions. Treatment with PF-562271 impaires cell viability in all cell lines, with an average IC50 of 2.4 μM after 3 days of treatment. TC32 and A673 are the 2 most sensitive cell lines, with IC50 concentrations of 2.1 and 1.7 μM, respectively[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 939791-41-0
-
Appearance Solid
-
Molecular Weight 543.95
-
Formula C21H21ClF3N7O3S
-
Color Light yellow to yellow
-
SMILES
CS(=O)(N(C1=NC=CC=C1CNC2=NC(NC3=CC4=C(NC(C4)=O)C=C3)=NC=C2C(F)(F)F)C)=O.[H]Cl
-
Synonyms
VS-6062hydrochloride
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (30)
-
Journal Impact Factor
-
Most Recent
-
Nat Biomed Eng
Nonexpansive biodegradable matrix promotes blood vessel organoid development for neurovascular repair and functional recovery in ischaemic stroke. [Abstract]2025 Nov 3. PMID: 41184604 -
Cancer Res
High-throughput tyrosine kinase activity profiling identifies FAK as a candidate therapeutic target in Ewing sarcoma. [Abstract]2013 May 1;73(9):2873-83. PMID: 23536552
PF-562271 hydrochloride purchased from MedChemExpress. Usage Cited in: Cancer Res. 2013 May 1;73(9):2873-83. [Abstract]
FAK inhibition downregulates the AKT/mTOR pathway and CAS activity. A, protein levels measured by Western immunoblotting for AKT/mTOR pathway proteins in A673 and TC32 cells serum-starved overnight, treated with PF-562271 for 6 hours, and then stimulated with IGF-1 for 2 hours. Vinculin is used as the loading control. B, Western immunoblots showing downregulation of phospho-CAS but not phospho-ERK in A673 and TC32 cells after treatment with PF-562271.
-
Autophagy
PTK2/FAK inhibition triggers TMED9-mediated protective autophagy in pancreatic cancer cell via enhancing ERGIC-ERES contact. [Abstract]2026 May 29:1-15. PMID: 42144738 -
Cell Discov
A positive mechanobiological feedback loop controls bistable switching of cardiac fibroblast phenotype. [Abstract]2022 Sep 6;8(1):84. PMID: 36068215 -
Carbohydr Polym
Inulin-like polysaccharide ABWW may impede CCl4 induced hepatic stellate cell activation through mediating the FAK/PI3K/AKT signaling pathway in vitro & in vivo. [Abstract]2024 Feb 15:326:121637. PMID: 38142102 -
Cell Death Dis
Identification of matrix-remodeling associated 5 as a possible molecular oncotarget of pancreatic cancer. [Abstract]2023 Feb 24;14(2):157. PMID: 36828810
PF-562271 hydrochloride purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2023 Feb 24;14(2):157. [Abstract]
PF-562271 (250 nM; 6 h) largely inhibits Akt-S6 phosphorylation in OE-MXRA5 priPC-1 cells.
-
Cell Death Dis
P130cas-FAK interaction is essential for YAP-mediated radioresistance of non-small cell lung cancer. [Abstract]2022 Sep 10;13(9):783. PMID: 36088346 -
Clin Cancer Res
High-throughput Chemical Screening Identifies Focal Adhesion Kinase and Aurora Kinase B Inhibition as a Synergistic Treatment Combination in Ewing Sarcoma. [Abstract]2019 Jul 15;25(14):4552-4566. PMID: 30979745 -
Int J Surg
Supervising the recurrence of pancreatic ductal adenocarcinoma using CtDNA-based MIR129-2 methylation detection. [Abstract]2025 Sep 17. PMID: 40961228 -
Am J Chin Med
Evodiamine Suppresses Lung Cancer Progression Through Modulating FAK/STAT3/AKT Signaling Pathway. [Abstract]2025;53(4):1225-1240. PMID: 40582716 -
World J Gastroenterol
FBP1 as a key regulator of focal adhesion kinase-mediated hepatic stellate cell activation: Multi-omics and experimental validation. [Abstract]2025 Jul 28;31(28):107361. PMID: 40741470 -
Cell Rep
Mechanotransduction in response to ECM stiffening impairs cGAS immune signaling in tumor cells. [Abstract]2023 Oct 5;42(10):113213. PMID: 37804510 -
Life Sci
Harmine inhibits the proliferation and migration of glioblastoma cells via the FAK/AKT pathway. [Abstract]2021 Apr 1:270:119112. PMID: 33508300 -
Breast Cancer Res
TMEM120B strengthens breast cancer cell stemness and accelerates chemotherapy resistance via β1-integrin/FAK-TAZ-mTOR signaling axis by binding to MYH9. [Abstract]2024 Mar 19;26(1):48. PMID: 38504374 -
Sci Rep
The mechanical microenvironment regulates ovarian cancer cell morphology, migration, and spheroid disaggregation. [Abstract]2018 May 8;8(1):7228. PMID: 29740072 -
Int J Cancer
2015 Oct 1;137(7):1549-59. PMID: 25809490
PF-562271 hydrochloride purchased from MedChemExpress. Usage Cited in: Int J Cancer. 2015 Oct 1;137(7):1549-59. [Abstract]
786-O (a) and Caki-1 (b) are treated for 24 and 48h with increasing concentrations of PF-562,271 and adherent cells were counted. Cell lysates are evaluated through immunoblotting for total FAK following treatment for 24h.
-
Cell Signal
Tenvermectin B, a novel macrocyclic lactone antibiotic, suppresses glioblastoma progression by targeting RhoJ. [Abstract]2025 Sep 10:136:112117. PMID: 40939916 -
Environ Toxicol Pharmacol
ZC3H4 Governs Epithelial Cell Migration through ROCK/p-PYK2/p-MLC2 Pathway in Silica-induced Pulmonary Fibrosis. [Abstract]2023 Nov:104:104301. PMID: 37866415 -
Eur J Cell Biol
The mechanical mechanism of angiotensin II induced activation of hepatic stellate cells promoting portal hypertension. [Abstract]2024 May 28;103(2):151427. PMID: 38820882 -
Cancer Med
Focal Adhesion Kinase Intersects With the BRD4-MYC Axis and YAP1 to Drive Tumor Cell Growth, Phenotypic Plasticity, Stemness, and Metastatic Potential in Colorectal Cancer. [Abstract]2025 Sep;14(18):e71227. PMID: 40959971 -
Mol Biol Rep
Piperlongumine inhibits the proliferation and migration of non-small cell lung cancer cells through the EGFR/FAK/STAT3 pathway. [Abstract]2026 May 14;53(1):770. PMID: 42133146 -
Mol Biol Rep
Ginkgetin inhibits the proliferation and migration of lung cancer cells via FAK/STAT3/AKT pathway. [Abstract]2025 May 14;52(1):458. PMID: 40366441 -
J Nat Med
2020 Sep;74(4):732-740. PMID: 32643027 -
Anticancer Drugs
2024 Jan 1;35(1):46-54. PMID: 37449977 -
-
-
bioRxiv
2025 Apr 7:2025.04.01.646098. PMID: 40291676 -
-
-
PF-562271 hydrochloride purchased from MedChemExpress. Usage Cited in: Practical Oncology Journal. 2015, 29(5): 444-449.
Effects and mechanism of Biglycan and FAK signaling pathway on the invasion and metastasis of colon cancer cells.
Solvent & Solubility
DMSO : 100 mg/mL (183.84 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (275 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Roberts WG, et al. Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271. Cancer Res, 2008, 68(6), 1935-1944. [Content Brief]
[2]. Crompton BD, et al. High-throughput tyrosine kinase activity profiling identifies FAK as a candidate therapeutic target in Ewing sarcoma. Cancer Res. 2013 May 1;73(9):2873-83. [Content Brief]
[3]. Bagi CM, et al. Dual focal adhesion kinase/Pyk2 inhibitor has positive effects on bone tumors: implications for bone metastases. Cancer. 2008 May 15;112(10):2313-21. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.8384 mL | 9.1920 mL | 18.3840 mL | 45.9601 mL |
| 5 mM | 0.3677 mL | 1.8384 mL | 3.6768 mL | 9.1920 mL | |
| 10 mM | 0.1838 mL | 0.9192 mL | 1.8384 mL | 4.5960 mL | |
| 15 mM | 0.1226 mL | 0.6128 mL | 1.2256 mL | 3.0640 mL | |
| 20 mM | 0.0919 mL | 0.4596 mL | 0.9192 mL | 2.2980 mL | |
| 25 mM | 0.0735 mL | 0.3677 mL | 0.7354 mL | 1.8384 mL | |
| 30 mM | 0.0613 mL | 0.3064 mL | 0.6128 mL | 1.5320 mL | |
| 40 mM | 0.0460 mL | 0.2298 mL | 0.4596 mL | 1.1490 mL | |
| 50 mM | 0.0368 mL | 0.1838 mL | 0.3677 mL | 0.9192 mL | |
| 60 mM | 0.0306 mL | 0.1532 mL | 0.3064 mL | 0.7660 mL | |
| 80 mM | 0.0230 mL | 0.1149 mL | 0.2298 mL | 0.5745 mL | |
| 100 mM | 0.0184 mL | 0.0919 mL | 0.1838 mL | 0.4596 mL |
PF-562271 hydrochloride Related Classifications
HY-20403 Related Classifications
Powered by Bioz